I/UCRC: Technology Innovation for Novel Cost-reducing and Quality-enhancing Musculoskeletal Therapies

I/UCRC：新型降低成本和提高质量的肌肉骨骼疗法的技术创新

• 批准号: 1361975
• 负责人: Jeffrey Lotz
• 金额: $ 52.05万
• 依托单位: University of California-San Francisco
• 依托单位国家: 美国
• 项目类别: Continuing Grant
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-15 至 2020-03-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1361975&HistoricalAwards=false
• 关键词: UCRC; Technology; Innovation; Novel; Cost

The I/UCRC for Disruptive Musculoskeletal Innovations intends to bring together expertise in medical device design; new advancements in materials, nano-technology, and medical imaging; computer modeling; clinical expertise in musculoskeletal care; business acumen for medical device innovation; and analysis of large national databases that include both clinical outcomes and cost data. By doing so, CDMI has the potential to advance knowledge by bridging these academic skills to pressing needs of the medical technology (MedTech) industry. CDMI plans to conduct research encompassing multiple disciplines, including material science, biomedical engineering, nanotechnology, biosensors, implant design, information technology, and advanced imaging that have the potential to reduce costs and improve outcomes.The med-tech industry has an important role in the US economy. However, US pre-market regulatory processes, combined with coverage and reimbursement uncertainties, create significant deterrents to innovation, and places America?s leadership position in jeopardy. Without confidence that a new medical technology will be paid for, industry cannot justify the investment required to bring that technology to market. As a result, there is a pressing societal need to create more value from the money spent on medical technology, and thereby manage healthcare cost increases without sacrificing the benefits of innovation. For the US to maintain its leadership in medical technologies, healthcare dollars need to be channeled in ways to foster innovation that is sustainable. The cooperative research efforts of the CDMI seek to provide, in part, a framework to achieve these ends.

I/UCRC for Disruptive Musculoskeletal Innovations旨在汇集医疗器械设计方面的专业知识;材料，纳米技术和医学成像的新进展;计算机建模;肌肉骨骼护理的临床专业知识;医疗器械创新的商业智慧;以及包括临床结果和成本数据的大型国家数据库的分析。通过这样做，CCENTRAL有可能通过将这些学术技能与医疗技术（MedTech）行业的迫切需求联系起来来推进知识。 该研究所计划开展涵盖多个学科的研究，包括材料科学、生物医学工程、纳米技术、生物传感器、植入物设计、信息技术和先进成像技术，这些技术有可能降低成本并改善结果。医疗技术行业在美国经济中发挥着重要作用。然而，美国上市前的监管程序，加上覆盖面和报销的不确定性，创造了重大的阻碍创新，并把美国？的领导地位处于危险之中。如果不相信一项新的医疗技术将得到支付，工业界就不能证明将该技术推向市场所需的投资是合理的。因此，社会迫切需要从医疗技术上花费的资金中创造更多价值，从而在不牺牲创新利益的情况下管理医疗成本的增加。美国要保持其在医疗技术领域的领导地位，医疗保健资金需要以可持续的方式促进创新。该委员会的合作研究努力在一定程度上寻求为实现这些目标提供一个框架。